Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients

Immune checkpoint inhibitors (ICI) are designed to activate exhausted tumor-reactive T cells thereby leading to tumor regression. Durvalumab, an ICI that binds to the programmed death ligand-1 (PD-L1) molecule, is approved as a consolidation therapy for treatment of patients with stage III, unresect...

Descripción completa

Detalles Bibliográficos
Autores principales: Naidus, Elliot, Bouquet, Jerome, Oh, David Y., Looney, Timothy J., Yang, Hai, Fong, Lawrence, Standifer, Nathan E., Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195930/
https://www.ncbi.nlm.nih.gov/pubmed/33420629
http://dx.doi.org/10.1007/s00262-020-02833-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195930/
https://www.ncbi.nlm.nih.gov/pubmed/33420629
http://dx.doi.org/10.1007/s00262-020-02833-z

Ejemplares similares